Tech Company Inital Public Offerings

Atreca IPO

Operating out of Redwood City, Atreca is now a public company.

Transaction Overview

Company Name
Announced On
6/19/2019
Transaction Type
IPO
Amount
$125,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: approximately $45 million to fund the development of ATRC-101 through the dose-escalation portion of our Phase 1b clinical trial and a portion of our currently planned protocol amendments to pursue combination studies and expansion cohorts; approximately $65 million to fund our ongoing efforts to develop additional clinical candidates from our discovery platform; and the remaining proceeds for continued development and utilization of our discovery platform, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Saginaw Dr.
Redwood City, CA 94063
USA
Email Address
Overview
Atreca (Nasdaq: BCEL) develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Profile
Atreca LinkedIn Company Profile
Social Media
Atreca Company Twitter Account
Company News
Atreca News
Facebook
Atreca on Facebook
YouTube
Atreca on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Orwin
  John Orwin LinkedIn Profile  John Orwin Twitter Account  John Orwin News  John Orwin on Facebook
Chief Financial Officer
Susan Berland
  Susan Berland LinkedIn Profile  Susan Berland Twitter Account  Susan Berland News  Susan Berland on Facebook
Chief Information Officer
Wayne Volkmuth
  Wayne Volkmuth LinkedIn Profile  Wayne Volkmuth Twitter Account  Wayne Volkmuth News  Wayne Volkmuth on Facebook
Chief Scientific Officer
Norman Greenberg
  Norman Greenberg LinkedIn Profile  Norman Greenberg Twitter Account  Norman Greenberg News  Norman Greenberg on Facebook
Chief Technical Officer
Guy Cavet
  Guy Cavet LinkedIn Profile  Guy Cavet Twitter Account  Guy Cavet News  Guy Cavet on Facebook
VP - Bus. Development
Paulette Dillon
  Paulette Dillon LinkedIn Profile  Paulette Dillon Twitter Account  Paulette Dillon News  Paulette Dillon on Facebook
VP - Bus. Development
Tito Serafini
  Tito Serafini LinkedIn Profile  Tito Serafini Twitter Account  Tito Serafini News  Tito Serafini on Facebook
VP - Finance
Jonathan Woo
  Jonathan Woo LinkedIn Profile  Jonathan Woo Twitter Account  Jonathan Woo News  Jonathan Woo on Facebook
VP - R & D
Jonathan Benjamin
  Jonathan Benjamin LinkedIn Profile  Jonathan Benjamin Twitter Account  Jonathan Benjamin News  Jonathan Benjamin on Facebook
VP - R & D
Daniel Emerling
  Daniel Emerling LinkedIn Profile  Daniel Emerling Twitter Account  Daniel Emerling News  Daniel Emerling on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/19/2019: AnyVision venture capital transaction
Next: 6/19/2019: RAPT Therapeutics venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary